New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 29, 2014
11:37 EDTRPRX, FTR, OTEX, TEF, VMC, TQNT, EXAS, CVC, EWH, GALTHigh option volume stocks
High option volume stocks: RPRX EWH CVC EXAS TQNT VMC TEF OTEX FTR GALT
News For RPRX;EWH;CVC;EXAS;TQNT;VMC;TEF;OTEX;FTR;GALT From The Last 14 Days
Check below for free stories on RPRX;EWH;CVC;EXAS;TQNT;VMC;TEF;OTEX;FTR;GALT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 22, 2014
13:57 EDTRPRXRepros Therapeutics volatility increases on wide price movement
Repros Therapeutics overall option implied volatility of 128 is above its 26-week average of 89 according to Track Data, suggesting large price movement.
09:18 EDTRPRXRepros Therapeutics provides update on Androxal
Subscribe for More Information
September 21, 2014
15:30 EDTVMCSummers calls for infrastructure spending to boost U.S. growth, Bloomberg says
Subscribe for More Information
September 19, 2014
14:56 EDTEXASExact Sciences volatility elevated
Exact Sciences October call option implied volatility is at 88, November is at 78, January is at 71; compared to its 26-week average of 66 according to Track Data, suggesting large near term price movement.
14:05 EDTFTRFrontier Communications partners with William Raveis Real Estate
Subscribe for More Information
10:07 EDTVMCHigh option volume stocks
Subscribe for More Information
08:11 EDTTQNTTriQuint chip among those in iPhone 6 Plus, iFixit reports
Subscribe for More Information
06:17 EDTTEFTelefonica acquires Brazil's GVT from Vivendi
Spanish telecom company Telefonica (TEF) agreed to buy Brazilian telecom unit Global Village Telecom, or GVT, from Vivendi (VIVHY) for EUR4.66B in cash as well as a payment in shares representing 12.0% of the share capital of Telefonica Brasil, after its integration with GVT. As part of the agreement, Vivendi has accepted Telefonica’s offer to acquire 1.1B ordinary shares held by Telefonica in Telecom Italia (TI), currently representing 8.3% of Telecom Italia’s voting share capital (corresponding to 5.7% of its total share capital), in exchange of 4.5% of Vivendi’s capital in the company resulting from the integration between Telefonica Brasil and GVT.
September 18, 2014
18:06 EDTTQNTTriQuint, RF Micro Devices announce new company name
RF Micro Devices (RFMD) and TriQuint Semiconductor (TQNT) revealed that the holding company under which the companies will combine in a merger of equals will be named Qorvo. Shareholders of both TriQuint and RFMD voted to approve the merger on September 5, and the transaction is expected to close in the second half of 2014, following other required regulatory approvals and satisfaction of customary closing conditions. Qorvo is expected to be traded on the NASDAQ Global Stock Market under the ticker symbol “QRVO” following closing of the merger.
13:38 EDTRPRXRepros needed unique Androxal label even before ADCOM panel, says Ladenburg
Ladenburg said that given the FDA advisory committee's 20 to 1 vote that it believes the FDA will likely revise testosterone replacement therapy labels to restrict their use in hypogonadal patients with clear etiology. However, Ladenburg added that Repros was always going to have to establish a unique label for Androxal and the firm believes that the company's ongoing and completed trials will provide sufficient data for filing and approval by the FDA in secondary hypogonadism. The firm maintains its Buy rating and $35 price target on Repros.
12:45 EDTRPRXOn The Fly: Midday Wrap
Subscribe for More Information
11:15 EDTRPRXRepros sinks after panel backs tests for testosterone therapies
Subscribe for More Information
10:52 EDTRPRXOptions with increasing implied volatility
Options with increasing implied volatility: RPRX VALE NLY AGNC
07:19 EDTRPRXRepros Therapeutics sell-off overdone, says Brean Capital
Brean Capital said the selling in Repros Therapeutics is overdone after an FDA panel voted overwhelmingly in support for a more restrictive label that limits the use of TRT drugs to only patients with classic hypogonadism. The firm feels since Androxal has not been targeting age-related hypogonadism it does not deserve to be negatively impacted by yesterday's ruling. Brean Capital maintains its Buy rating on Repros Therapeutics and $41 price target on the shares.
07:00 EDTRPRXRepros Therapeutics price target lowered to $13 from $24 at Piper Jaffray
Subscribe for More Information
06:10 EDTRPRXFDA panel votes 20-1 to study changes to testosterone therapies
Subscribe for More Information
06:05 EDTTEFAmazon partners with Bango, Telefonica Deutschland on carrier billing services
Subscribe for More Information
September 17, 2014
09:22 EDTTEFTelecom Italia not holding talks with Oi, Tim Participacoes says,Reuters reports
Subscribe for More Information
September 16, 2014
11:18 EDTTEFTelecom Italia says mulling buyout of Oi S.A., Bloomberg says
Subscribe for More Information
07:27 EDTFTRBofA/Merrill to hold a conference
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use